Home › Employers › Time Therapeutics, Inc.
Time Therapeutics, Inc.: H-1B salaries and sponsorship
Time Therapeutics, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $135,346.
Does Time Therapeutics, Inc. sponsor H-1B visas?
Time Therapeutics, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on May 6, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Data Engineer III | 2 | $135,346 |
| Vice President of Analytics | 1 | $300,000 |
| Growth Marketing Lead | 1 | $120,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 2 | $210,000 |
| FY2026 | 2 | $135,346 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Data Engineer III | $135,346 Level III | Tampa, FL | May 6, 2026 | Oct 1, 2026 | Certified |
| Data Engineer III | $135,346 Level III | Tampa, FL | May 1, 2026 | Oct 1, 2026 | Certified |
| Growth Marketing Lead | $120,000–$180,000 E-3 · Level I | New York, NY | Aug 28, 2024 | Sep 9, 2024 | Certified |
| Vice President of Analytics | $300,000 Level IV | New York, NY | Nov 8, 2023 | Nov 13, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).